These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 32747365)

  • 1. Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.
    Geistlinger L; Oh S; Ramos M; Schiffer L; LaRue RS; Henzler CM; Munro SA; Daughters C; Nelson AC; Winterhoff BJ; Chang Z; Talukdar S; Shetty M; Mullany SA; Morgan M; Parmigiani G; Birrer MJ; Qin LX; Riester M; Starr TK; Waldron L
    Cancer Res; 2020 Oct; 80(20):4335-4345. PubMed ID: 32747365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
    Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
    Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
    Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K
    Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
    Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O
    BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
    Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
    Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating single-cell and spatial transcriptomic analysis to unveil heterogeneity in high-grade serous ovarian cancer.
    Luo H; Wang K; Li B
    Front Immunol; 2024; 15():1420847. PubMed ID: 38975339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites.
    Feigenberg T; Clarke B; Virtanen C; Plotkin A; Letarte M; Rosen B; Bernardini MQ; Kollara A; Brown TJ; Murphy KJ
    Biomed Res Int; 2014; 2014():367103. PubMed ID: 24982872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.
    Murakami R; Matsumura N; Mandai M; Yoshihara K; Tanabe H; Nakai H; Yamanoi K; Abiko K; Yoshioka Y; Hamanishi J; Yamaguchi K; Baba T; Koshiyama M; Enomoto T; Okamoto A; Murphy SK; Mori S; Mikami Y; Minamiguchi S; Konishi I
    Am J Pathol; 2016 May; 186(5):1103-13. PubMed ID: 26993207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer.
    Xu J; Fang Y; Chen K; Li S; Tang S; Ren Y; Cen Y; Fei W; Zhang B; Shen Y; Lu W
    Clin Cancer Res; 2022 Aug; 28(16):3590-3602. PubMed ID: 35675036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.
    Wang C; Armasu SM; Kalli KR; Maurer MJ; Heinzen EP; Keeney GL; Cliby WA; Oberg AL; Kaufmann SH; Goode EL
    Clin Cancer Res; 2017 Aug; 23(15):4077-4085. PubMed ID: 28280090
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
    Zhang Q; Wang C; Cliby WA
    Gynecol Oncol; 2019 Feb; 152(2):368-374. PubMed ID: 30448260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification.
    Hollis RL; Meynert AM; Michie CO; Rye T; Churchman M; Hallas-Potts A; Croy I; McCluggage WG; Williams ARW; Bartos C; Iida Y; Okamoto A; Dougherty B; Barrett JC; March R; Matakidou A; Roxburgh P; Semple CA; Harkin DP; Kennedy R; Herrington CS; Gourley C
    Clin Cancer Res; 2022 Aug; 28(16):3546-3556. PubMed ID: 35696721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.
    Pradhan M; Risberg BA; Tropé CG; van de Rijn M; Gilks CB; Lee CH
    BMC Cancer; 2010 Sep; 10():493. PubMed ID: 20843305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study.
    Dugo M; Devecchi A; De Cecco L; Cecchin E; Mezzanzanica D; Sensi M; Bagnoli M
    Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31491988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.
    Leonard B; Starrett GJ; Maurer MJ; Oberg AL; Van Bockstal M; Van Dorpe J; De Wever O; Helleman J; Sieuwerts AM; Berns EM; Martens JW; Anderson BD; Brown WL; Kalli KR; Kaufmann SH; Harris RS
    Clin Cancer Res; 2016 Sep; 22(18):4746-55. PubMed ID: 27016308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
    Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
    Front Immunol; 2022; 13():923194. PubMed ID: 35935940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
    Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
    J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancer.
    Nakamura K; Reid BM; Chen A; Chen Z; Goode EL; Permuth JB; Teer JK; Tyrer J; Yu X; Kanetsky PA; Pharoah PD; Gayther SA; Sellers TA; Lawrenson K; Karreth FA
    Am J Hum Genet; 2022 Jan; 109(1):116-135. PubMed ID: 34965383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.
    Olbrecht S; Busschaert P; Qian J; Vanderstichele A; Loverix L; Van Gorp T; Van Nieuwenhuysen E; Han S; Van den Broeck A; Coosemans A; Van Rompuy AS; Lambrechts D; Vergote I
    Genome Med; 2021 Jul; 13(1):111. PubMed ID: 34238352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.